Amy Feldman, MD
Abramson Cancer Center of the University of Pennsylvania
Last Modified: July 23, 2006
Acute lymphoblastic leukemia, also known as acute lymphocytic leukemia or ALL, is a cancer arising from the bone marrow. Specifically, it is a type of cancer that affects the white blood cells, those cells in our body responsible for fighting off infection. In ALL, too many immature white blood cells (lymphoblasts) are produced, and they begin to replace the normal blood cells in the bone marrow. ALL is the most common cancer to occur in children and it accounts for over one-fourth of all cases of pediatric cancer. In the United States, approximately 4,500 new cases of ALL are diagnosed each year in people less than 25 years of age. The peak incidence occurs between 2 and 5 years of age. ALL occurs more commonly in males than females and more frequently in Caucasians than African-Americans. Children with certain genetic conditions, including Down's Syndrome and immunodeficiencies are at greater risk for developing ALL. Advances in treatment have greatly increased the survival rates for pediatric ALL patients, and over 80% of children obtain 5-year survival.
The presenting symptoms of ALL result from bone marrow infiltration and disease spread. ALL primarily affects the white blood cells which are cells responsible for fighting off infection. Therefore, children with ALL often present with a repeated series of infections. The abnormal white cells take over the bone marrow resulting in lower numbers of normal red blood cells (which are responsible for carrying oxygen) and platelets (which are responsible for helping to stop bleeding after injury). As a result, children with ALL can be pale and tired, and often experience bruising and bleeding. In addition, children with ALL can present with fever, bone and joint pain, weight loss, difficulty breathing, swollen lymph nodes, or enlargement of the liver and spleen. In children with disease present in the central nervous system, headache and vomiting can be the initial symptoms. In boys with testicular ALL, a unilateral painless swollen testicle may be the presenting symptom.
A careful history and physical examination, along with laboratory tests will help determine if a child has ALL.
ALL is by definition a systemic disease, as the cancer has traveled all over the body and is not localized to one specific spot. Therefore chemotherapy is the main form of treatment. Successful treatment involves administration of multiple different chemotherapy drugs, divided into several phases that occur over two to three years. The four stages of treatment are: induction, consolidation, intensification, and maintenance. The aim of induction therapy is to get the child into remission, defined as less than 5% blasts in the marrow. After remission has been achieved, consolidation, intensification, and maintenance therapy occur to keep the cancer in remission and prevent emergence of drug resistance. Successful treatment of ALL also involves the delivery of chemotherapy into the central nervous system. Irradiation of the central nervous system may be utilized to additionally target any cancer cells that might be present in the brain or spinal cord
Relapses most frequently occur in the bone marrow; however, relapse can also occur in the central nervous system, the testis, the ovary, and the eye. Most relapsed leukemias retain their original molecular characteristics, but sometimes cellular changes can occur known as a "lineage switch." Relapse protocols include more intense chemotherapy, bone marrow transplantation, or localized radiation.
Although survival rates for children with ALL were not always high, advances in finding effective chemotherapy agents has increased the 5-year survival rate to around 80%. Important factors influencing prognosis include: white blood cell (WBC) count at the time of diagnosis, patient age and sex, initial response to induction therapy, and certain molecular features of the cancer cells. WBC count less than 50,000, age between one and ten years, hyperdiploid cells, female gender, and good response to induction therapy are all factors equated with a better prognosis.
Although no specific risk factors have been shown to cause ALL, children who have Down's syndrome, Neurofibromatosis type 1, Bloom syndrome, and ataxia telangiectasia experience ALL at higher rates than the general population.
"Acute lymphoblastic leukemia." Emedicine.com.
"Acute Lymphoblastic Leukemia." National Cancer Institute web site.
Buffler, PA, Kwan, ML, Reynolds, P, Urayama, KY. Environmental and genetic risk factors for childhood leukemia: Appraising the evidence. Cancer Investigation 2005; 23:60.
Greenlee RT, Murray T, Bolden S, et al. "Cancer statistics 2000." CA Cancer J Clin 2000; 50: 7-33.
Gurney, JG, Bondy, ML. Epidemiologic research methods and childhood cancer. In: Principles and Practice of Pediatric Oncology (4th ed), Pizzo, PA, Poplack, DG (Eds), Lippincott-Raven, Philadelphia, 2001. p.13.
Jemal A, Tiwari RC, Murray T, et al. "Cancer statistics 2004." CA Cancer J Clin 2004:54:8-29.
Margolin J, Steuber CP, Poplack D. "Acute Lymphoblastic Leukemia." In: Principles and Practice of Pediatric Oncology 5 th Edition, Pizzo, PA, Poplack, DG (Eds), Lippincott, Williams, and Wilkins, 2006. p538-590.
Moorman, AV, Richards, SM, Martineau, M, et al. "Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia." Blood 2003; 102:2756.
Pui CH, Boyett JM, Relling MV, et al. "Sex differences in prognosis for children with acute lymphoblastic leukemia." Journal of Clinical Oncology 1999; 17:818-824.
SEER Cancer Statistic Review, 1973-1999. National Cancer Institute, Bethesda, MD, 2000. p.467.
Jul 25, 2011 - Pediatric patients with high-risk leukemia, either acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL), who are treated with contemporary protocols have improved survival compared to earlier cohorts and have a favorable outcome after hematopoietic cell transplantation (HCT), regardless of donor type, according to a study published in the July 14 issue of Blood.